Neurocrine Biosciences, Inc.NBIXNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +24.72% | +21.84% | +11.12% | +16.49% | +27.78% |
| Gross Profit Growth | +25.94% | +22.04% | +10.95% | +16.39% | +27.16% |
| EBITDA Growth | +30.40% | -11.37% | -71.93% | -1.48% | +56.56% |
| Operating Income Growth | +30.17% | -5.52% | -76.23% | +0.14% | +30.03% |
| Net Income Growth | +56.20% | -30.20% | -81.80% | +65.38% | +61.40% |
| EPS Growth | +50.59% | -31.33% | -81.40% | +70.31% | +64.84% |
| EPS Diluted Growth | +51.22% | -30.56% | -80.95% | +68.25% | +64.52% |
| Weighted Average Shares Growth | +3.27% | +1.63% | -0.10% | -1.79% | -1.68% |
| Weighted Average Shares Diluted Growth | +3.17% | +0.59% | -1.06% | -2.79% | -1.73% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -25.47% | +96.36% | -50.27% | +57.89% | +43.99% |
| Free Cash Flow Growth | -26.66% | +99.15% | -54.58% | +68.87% | +42.96% |
| Receivables Growth | +15.15% | +9.06% | +14.49% | +27.23% | +51.32% |
| Inventory Growth | +59.03% | +49.87% | +58.87% | +33.88% | +51.31% |
| Asset Growth | +24.11% | +14.37% | +6.20% | +17.69% | +20.67% |
| Book Value per Share Growth | +31.50% | +14.17% | +6.38% | +9.33% | +12.36% |
| Debt Growth | -8.11% | +6.23% | -12.58% | +71.39% | +70.41% |
| R&D Expense Growth | +37.13% | +34.98% | +65.12% | +27.84% | +28.21% |
| SG&A Expenses Growth | +14.74% | +31.48% | +13.74% | +18.31% | +24.46% |